hemospray
Jump to navigation
Jump to search
Indications
- treatment of GI bleeding during GI endoscopy
- upper GI bleed during upper GI endoscopy
- lower GI bleed during lower GI endoscopy
- can be used over large areas, including large tumors & ulcers
Contraindications
- variceal bleeding: esophageal varices, gastric varices
- GI fisutla
- high risk of intestinal perforation
Mechanism of action
- delivers a mineral powder to the bleeding site during GI endoscopy
- when the powder contacts blood, it creates a gel that forms a stable mechanical barrier that covers the bleeding
- stops bleeding within 5 minutes in 95% of cases
- 20% experience rebleeding within 30 days (generally within 3 days)
Complications
More general terms
References
- ↑ FDA News Release. May 7, 2018 FDA permits marketing of new endoscopic device for treating gastrointestinal bleeding https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm606799.htm